New approval for drug gives Novartis excuse to up promotion
The newest indication for Reclast -- postmenopausal osteoporosis -- ups its market potential considerably, analysts said.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.